annual CFF:
$331.98M+$269.32M(+429.78%)Summary
- As of today (September 15, 2025), CRSP annual cash flow from financing activities is $331.98 million, with the most recent change of +$269.32 million (+429.78%) on December 31, 2024.
- During the last 3 years, CRSP annual CFF has risen by +$81.04 million (+32.29%).
- CRSP annual CFF is now -67.33% below its all-time high of $1.02 billion, reached on December 31, 2020.
Performance
CRSP Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$2.26M-$8.33M(-78.67%)Summary
- As of today (September 15, 2025), CRSP quarterly cash flow from financing activities is $2.26 million, with the most recent change of -$8.33 million (-78.67%) on June 30, 2025.
- Over the past year, CRSP quarterly CFF has increased by +$2.72 million (+584.55%).
- CRSP quarterly CFF is now -99.56% below its all-time high of $512.89 million, reached on September 30, 2020.
Performance
CRSP quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$39.36M+$2.72M(+7.43%)Summary
- As of today (September 15, 2025), CRSP TTM cash flow from financing activities is $39.36 million, with the most recent change of +$2.72 million (+7.43%) on June 30, 2025.
- Over the past year, CRSP TTM CFF has dropped by -$306.60 million (-88.62%).
- CRSP TTM CFF is now -96.83% below its all-time high of $1.24 billion, reached on March 31, 2021.
Performance
CRSP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CRSP Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +429.8% | +584.5% | -88.6% |
| 3 y3 years | +32.3% | -78.2% | +4.9% |
| 5 y5 years | -23.0% | -97.5% | -91.6% |
CRSP Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +760.2% | -99.3% | +584.5% | -89.2% | +50.2% |
| 5 y | 5-year | -67.3% | +760.2% | -99.6% | +584.5% | -96.8% | +50.2% |
| alltime | all time | -67.3% | >+9999.0% | -99.6% | +150.5% | -96.8% | +1411.6% |
CRSP Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $2.26M(-78.7%) | $39.36M(+7.4%) |
| Mar 2025 | - | $10.59M(-37.3%) | $36.64M(-89.0%) |
| Dec 2024 | $331.98M(+429.8%) | $16.88M(+75.1%) | $331.98M(-6.2%) |
| Sep 2024 | - | $9.64M(-2168.7%) | $354.05M(+2.3%) |
| Jun 2024 | - | -$466.00K(-100.2%) | $345.96M(-4.7%) |
| Mar 2024 | - | $305.93M(+685.7%) | $363.19M(+479.6%) |
| Dec 2023 | $62.66M(+62.4%) | $38.94M(+2402.5%) | $62.66M(+139.1%) |
| Sep 2023 | - | $1.56M(-90.7%) | $26.20M(-34.1%) |
| Jun 2023 | - | $16.77M(+210.2%) | $39.76M(+19.2%) |
| Mar 2023 | - | $5.40M(+118.1%) | $33.35M(-13.6%) |
| Dec 2022 | $38.59M(-84.6%) | $2.48M(-83.6%) | $38.59M(-9.0%) |
| Sep 2022 | - | $15.11M(+46.0%) | $42.41M(+13.1%) |
| Jun 2022 | - | $10.35M(-2.8%) | $37.51M(+5.4%) |
| Mar 2022 | - | $10.65M(+69.1%) | $35.60M(-85.8%) |
| Dec 2021 | $250.94M(-75.3%) | $6.30M(-38.3%) | $250.94M(-61.8%) |
| Sep 2021 | - | $10.21M(+21.0%) | $657.27M(-43.3%) |
| Jun 2021 | - | $8.44M(-96.3%) | $1.16B(-6.5%) |
| Mar 2021 | - | $225.99M(-45.2%) | $1.24B(+22.1%) |
| Dec 2020 | $1.02B | $412.63M(-19.5%) | $1.02B(+11.9%) |
| Sep 2020 | - | $512.89M(+473.0%) | $908.24M(+94.8%) |
| Jun 2020 | - | $89.50M(+7806.8%) | $466.24M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $1.13M(-99.6%) | $406.39M(-5.7%) |
| Dec 2019 | $430.98M(+36.4%) | $304.72M(+329.9%) | $430.98M(+244.8%) |
| Sep 2019 | - | $70.89M(+139.0%) | $125.00M(-48.4%) |
| Jun 2019 | - | $29.65M(+15.3%) | $242.33M(+12.0%) |
| Mar 2019 | - | $25.73M(-2127.3%) | $216.41M(-31.5%) |
| Dec 2018 | $315.93M(>+9900.0%) | -$1.27M(-100.7%) | $315.93M(-0.8%) |
| Sep 2018 | - | $188.22M(+4947.5%) | $318.49M(+143.4%) |
| Jun 2018 | - | $3.73M(-97.0%) | $130.87M(+2.4%) |
| Mar 2018 | - | $125.25M(+9654.8%) | $127.84M(+4809.2%) |
| Dec 2017 | $2.61M(-98.6%) | $1.28M(+110.8%) | $2.60M(-97.2%) |
| Sep 2017 | - | $609.00K(-12.0%) | $93.09M(+5.8%) |
| Jun 2017 | - | $692.00K(+3542.1%) | $88.01M(-40.6%) |
| Mar 2017 | - | $19.00K(-100.0%) | $148.24M(-19.1%) |
| Dec 2016 | $183.22M(+89.4%) | $91.77M(-2152.5%) | $183.22M(+100.3%) |
| Sep 2016 | - | -$4.47M(-107.3%) | $91.45M(-4.7%) |
| Jun 2016 | - | $60.92M(+74.1%) | $95.92M(+9.1%) |
| Mar 2016 | - | $35.00M(-33.9%) | $87.96M(+51.0%) |
| Dec 2015 | $96.73M(+1788.2%) | - | - |
| Jun 2015 | - | $52.96M(+900.5%) | $58.25M(+1000.5%) |
| Mar 2015 | - | $5.29M | $5.29M |
| Dec 2014 | $5.12M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual cash flow from financing activities?
- What is the all time high annual CFF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual CFF year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly CFF year-on-year change?
- What is CRISPR Therapeutics AG TTM cash flow from financing activities?
- What is the all time high TTM CFF for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM CFF year-on-year change?
What is CRISPR Therapeutics AG annual cash flow from financing activities?
The current annual CFF of CRSP is $331.98M
What is the all time high annual CFF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash flow from financing activities is $1.02B
What is CRISPR Therapeutics AG annual CFF year-on-year change?
Over the past year, CRSP annual cash flow from financing activities has changed by +$269.32M (+429.78%)
What is CRISPR Therapeutics AG quarterly cash flow from financing activities?
The current quarterly CFF of CRSP is $2.26M
What is the all time high quarterly CFF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash flow from financing activities is $512.89M
What is CRISPR Therapeutics AG quarterly CFF year-on-year change?
Over the past year, CRSP quarterly cash flow from financing activities has changed by +$2.72M (+584.55%)
What is CRISPR Therapeutics AG TTM cash flow from financing activities?
The current TTM CFF of CRSP is $39.36M
What is the all time high TTM CFF for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM cash flow from financing activities is $1.24B
What is CRISPR Therapeutics AG TTM CFF year-on-year change?
Over the past year, CRSP TTM cash flow from financing activities has changed by -$306.60M (-88.62%)